Anastrozole, a third-generation aromatase inhibitor, has been used for more than 20 years to treat postmenopausal women with oestrogen receptor-positive breast cancer by blocking oestrogen production in the body [9]. The gene discussed is CYP19A1; the disease is breast carcinoma.